as 09-18-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | WESTLAKE VILLAGE |
Market Cap: | 2.1B | IPO Year: | 2020 |
Target Price: | $19.00 | AVG Volume (30 days): | 1.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.74 | EPS Growth: | N/A |
52 Week Low/High: | $8.03 - $18.15 | Next Earning Date: | 11-05-2025 |
Revenue: | $263,464,999 | Revenue Growth: | 99.50% |
Revenue Growth (this year): | 72.46% | Revenue Growth (next year): | 31.69% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Watanabe Todd Franklin | ARQT | See Remarks | Sep 9 '25 | Sell | $17.52 | 504 | $8,829.02 | 891,440 | |
Watanabe Todd Franklin | ARQT | See Remarks | Sep 8 '25 | Sell | $17.54 | 9,625 | $168,799.40 | 891,440 | |
Matsuda Masaru | ARQT | See Remarks | Sep 4 '25 | Sell | $16.16 | 36,130 | $583,716.28 | 161,234 | |
Welgus Howard G. | ARQT | Director | Sep 2 '25 | Sell | $15.64 | 10,000 | $156,383.00 | 100,206 | |
Burnett Patrick | ARQT | See Remarks | Aug 21 '25 | Sell | $15.57 | 2,438 | $37,968.92 | 104,811 | |
Burnett Patrick | ARQT | See Remarks | Aug 19 '25 | Sell | $16.16 | 1,750 | $28,280.70 | 104,811 | |
Burnett Patrick | ARQT | See Remarks | Aug 8 '25 | Sell | $14.03 | 3,847 | $53,988.41 | 104,811 |
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Investor's Business Daily
6 days ago
Zacks
7 days ago
Insider Monkey
7 days ago
Simply Wall St.
8 days ago
Insider Monkey
9 days ago
GlobeNewswire
13 days ago
GlobeNewswire
a month ago
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.